Roche lung cancer drug Alecensa slashes brain risk in tests

(Reuters) - Patients taking Roche's targeted lung cancer drug Alecensa have a far lower risk of their disease spreading in the brain than those on Pfizer's Xalkori, new clinical trial data show.